Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 abatacept induction and maintenance study in active Crohn's disease
NL-OMON30746Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abatacept in Crohn's disease (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Induction clinical response at Weeks 8 and 12, Maintenance clinical remission at 12 months and 1 more. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
abatacept
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON30746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30746.